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Abstract
Objectives To estimate life expectancy for people with HIV undergoing
treatment compared with life expectancy in the general population and
to assess the impact on life expectancy of late treatment, defined as
CD4 count <200 cells/mm3 at start of antiretroviral therapy.
Design Cohort study.
Setting Outpatient HIV clinics throughout the United Kingdom.
Population Adult patients from the UK Collaborative HIV Cohort (UK
CHIC) Study with CD4 count ≤350 cells/mm3 at start of antiretroviral
therapy in 1996-2008.
Main outcome measures Life expectancy at the exact age of 20 (the
average additional years that will be lived by a person after age 20),
according to the cross sectional age specific mortality rates during the
study period.
Results 1248 of 17 661 eligible patients died during 91 203 person
years’ follow-up. Life expectancy (standard error) at exact age 20
increased from 30.0 (1.2) to 45.8 (1.7) years from 1996-9 to 2006-8. Life
expectancy was 39.5 (0.45) for male patients and 50.2 (0.45) years for
female patients compared with 57.8 and 61.6 years for men and women
in the general population (1996-2006). Starting antiretroviral therapy
later than guidelines suggest resulted in up to 15 years’ loss of life: at
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age 20, life expectancy was 37.9 (1.3), 41.0 (2.2), and 53.4 (1.2) years
in those starting antiretroviral therapy with CD4 count <100, 100-199,
and 200-350 cells/mm3, respectively.
Conclusions Life expectancy in people treated for HIV infection has
increased by over 15 years during 1996-2008, but is still about 13 years
less than that of the UK population. The higher life expectancy in women
is magnified in those with HIV. Earlier diagnosis and subsequent timely
treatment with antiretroviral therapy might increase life expectancy.
Introduction
HIV infection has become a chronic disease with a good
prognosis provided treatment is started sufficiently early in the
course of the disease and the patient is able to maintain lifelong
adherence to antiretroviral therapy.1 2 Mortality rates have
decreased such that, compared with the general population, the
risk of death in successfully treated patients is similar to that of
people with unhealthy lifestyles (such as heavy smoking,
drinking, or obesity) or other chronic conditions such as
diabetes.3 Although previous studies have compared mortality
rates in patients with HIVwith those in the general population3-6
or have reported the prognosis of patients with HIV by
estimating cumulative probability of death,7 few have estimated
how long those with HIV are likely to live.
Estimates of life expectancy are important to individuals who
want to plan their lives better, to service providers, and to policy
makers. Patients might use this information to inform decisions
on when they start antiretroviral therapy and treatment of
comorbidities, pension provision, starting a family, or buying
a house. Service providers require estimates of life expectancy
to project the number of people with HIV who will need
treatment and the future costs of providing antiretroviral therapy.
Policy makers in the health service will be interested in
addressing inequalities in life expectancy between patients with
different characteristics, such as race or sex, or between those
with early or delayed initiation of antiretroviral therapy.8
Life expectancy in the general population varies by age, sex,
and race,9 and there are substantial differences between low and
high income countries, which are reflected in different mortality
rates in people with HIV.10 Furthermore, the pattern of the HIV
epidemic varies by country.11 Life expectancy in populations
with HIV has been estimated in specific countries12-15 and in
collaborations of cohorts6 16 but not in the United Kingdom.
We estimated life expectancy in those treated for HIV infection
and compared this with the life expectancy of the general
population in the UK using data from the UK Collaborative
HIV Cohort (UK CHIC) Study11 for 1996-2008. We also
estimated the loss in life expectancy of those who start
antiretroviral therapy at a more advanced stage of the disease
than recommended by national treatment guidelines and
quantified the potential years of life lost as a measure of the
burden of HIV disease at the population level in the UK.
Methods
Cohort description
The UK CHIC Study started in 2001 and collates routine data
on people with HIV attending some of the largest clinical centres
in the UK from 1 January 1996 (see appendix 1 on bmj.com).
In accordance with the data protection policy, data were
provided in an anonymised format with all names removed and
replaced by first name initial and a soundex code derived from
the patient’s surname. To be included in the UK CHIC Study
people had to be positive for HIV infection, have attended one
of the collaborating centres at any time since 1996, and be aged
16 or over.11
Selection of patients
Patients included in this analysis were all aged 20 and over and
had started treatment with antiretroviral therapy with at least
three drugs between 1 January 1996 and 31 December 2008.
We excluded patients with incomplete data on demographic
variables (age, sex, and ethnicity) and those whose assumed
transmission was through use of injected drugs because of the
low prevalence and worse prognosis compared with other risk
groups. We also excluded patients who started antiretroviral
therapy with a recorded CD4 cell count >350 cells/mm3 as
current UK treatment guidelines17 recommend that treatment
should be started at below this threshold in people with
asymptomatic HIV infection, and treatment at higher CD4
counts is generally recommended only for specific subgroups
of patients (such as pregnant women, those with symptomatic
infection or other comorbidities) whose outcomes might be
expected to differ. Patients with missing baseline CD4 count
were included in the study population. Patients were followed
up from start of antiretroviral therapy for all cause mortality,
which was ascertained from clinic records and by linkage to
national surveillance data on deaths.
Statistical methods
We calculated crude mortality rates (per 1000 person years) for
all ages and for individuals aged 20-44. Potential years of life
lost18 were calculated as the sum of years lost because of
premature death; this was defined as death before age 65, which
is the age at which most people retire in the UK. Potential years
of life lost were expressed per 1000 person years from age 20
to 64. Abridged life tables were constructed from age specific
mortality rates grouped in five year age bands to estimate life
expectancy from the age of 20 to 65. These tables describe the
mortality experience that hypothetical cohorts of people with
HIV would have had if they were subjected to the mortality in
the observed period. Life expectancy at an exact age is the
average additional years that will be lived by a person after that
age, according to the cross sectional age specific mortality rates
for all causes during the study period.
Mortality rates for the open age grouping (≥65) could not be
meaningfully estimated because there were too few older
patients to allow further stratification by age. Therefore the rate
of death in those aged ≥65 was adjusted by using the rate ratio
of mortality in the HIV positive population to that of the UK
population. We assumed that the rate ratio in those aged ≥65
was the same as the average rate ratio of the 55-59 and 60-64
age groups. We estimated rate adjustments separately for each
period in the analysis: these were 5.69, 2.76, 2.73, and 2.01 for
1996-9, 2000-2, 2003-5, and 2006-8, respectively. The overall
rate adjustment for 1996-2008 was 2.56, and we used this value
to adjust other analyses that were not divided by period of
follow-up. We investigated the sensitivity of estimates of life
expectancy over the period 1996-2008 to the adjustment used
by varying the rate adjustment from 1 (no adjustment) to 6.
Health indicators were calculated overall and stratified by
calendar period of follow-up (1996-9, 2000-2, 2003-5, 2006-8),
sex, CD4 count measured in the three months before starting
antiretroviral therapy (0-99, 100-199, 200-350 cells/mm3), and
the period in which antiretroviral therapy was started. The
analysis stratifying by CD4 included patients who started
treatment after 2000 and had no previous exposure to
antiretroviral drugs before starting antiretroviral therapy with
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three or more drugs so that the results should be applicable to
patients who currently start treatment. Patients without a CD4
count recorded at start of antiretroviral therapy were excluded
from this analysis. Initiation of antiretroviral therapy was the
start of follow-up for all analyses and is denoted as the
“baseline.” As the highest mortality rate was in the first six
months of antiretroviral therapy, we repeated the calculations
restricting analyses to those who survived at least six months
after starting treatment. We also investigated whether life
expectancy varied by ethnicity and sex (white men, non-white
men, white women, non-white women). For comparison, we
calculated health indicators for men and women in the UK
population using data from 1996 to 2006. Number of deaths
and person years at risk were extracted from the website www.
mortality.org in five year age bands. Detailed information on
the calculation of life tables and potential years of life lost have
been published previously.16 Analyses were done with Stata
version 11 and Microsoft Excel 2008.
Results
The UKCHIC Study included data on 35 377 people with HIV,
of whom 22 876 started antiretroviral therapy in 1996-2008.
We excluded one patient with missing age and 315 who were
aged under 20, 820 (4%) with an assumed risk transmission
through use of injected drugs, 3137 (14%) known to have started
antiretroviral therapy with a CD4 count above the recommended
treatment threshold of 350 cells/mm3, 743 (3%) with missing
ethnicity, and 199 with no follow-up time recorded. This left
17 661 patients eligible for inclusion in the analyses.
Table 1⇓ shows the characteristics of patients at baseline by the
period in which they started antiretroviral therapy and overall.
The proportions of white people, men, and men who have sex
with men were higher in 1996-9 compared with later periods.
Compared with later periods, patients who started antiretroviral
therapy in 1996-9 weremore immunosuppressed and weremore
likely to have had a diagnosis of AIDS. Patients had a median
follow-up of 5.1 (interquartile range 2.2-8.9) years. During the
91 203 person years of follow-up 1248 (7%) patients died.
Table 2⇓ shows the time trends in health indicators by period
of follow-up. Life expectancy at the exact age of 20 increased
by nearly 16 years from 1996-9 to 2006-8, and there was a linear
trend (P<0.001) across period of follow-up for overall mortality
andmortality at age 20-44. For a hypothetical cohort of patients
starting antiretroviral therapy at age 20 and experiencing the
age specific death rates observed during 1996-9, the proportion
surviving to age 45 would have been slightly over 60%. This
figure increased to over 80% when we used the death rates
experienced from 2003 onwards. During these years there was
a corresponding shift in the distribution of measurements of
CD4 counts (fig 1⇓). Each measurement was included as an
independent observation and assigned to the relevant period of
follow-up (the frequency of CD4 monitoring did not change
greatly over the study period). In 1996-9, 38% of measurements
were <200 cells/mm3 and 34% were >350 cells/mm3, whereas
in 2006-8 the proportions were 12% and 65%, respectively.
Table 3⇓ shows the life expectancy for men and women with
HIV undergoing treatment during the study period and, for
comparison, the life expectancy of theUKpopulation. Compared
with the same sex in the general UK population, for patients
undergoing treatment for HIV infection, life expectancy at age
20 was 18.3 years less for men and 11.4 years less for women.
Compared with men, the life expectancy of women was greater
by just less than four years, but this difference is magnified in
those treated for HIV, where the gap was over 10 years.
To show the potential effect of late treatment on life expectancy,
we estimated health indicators stratified by CD4 count for
patients who had not previously received any antiretroviral drugs
and started therapy with three or more drugs after 2000, when
non-nucleoside reverse transcriptase inhibitors were widely
available. Out of 11 812 patients who started antiretroviral
therapy in 2000-8, 664 (6%) were pre-treated with one or two
drugs and were not eligible for inclusion. Of the 11 148 eligible
patients, 9657 (87%) had a CD4 count recorded at baseline and
were included in the analysis. Figure 2⇓ shows life expectancy
between the ages of 20 and 65 in those with HIV stratified by
CD4 count compared with the life expectancy of men and
women in the UK population. Table 4⇓ shows that life
expectancy decreased by over 10 years in those starting
antiretroviral therapy with CD4 <200 cells/mm3compared with
200-350 cells/mm3. The population impact of premature
mortality before the age of 65 is illustrated by the difference in
potential years of life lost, which increased by a factor of three
for patients who started with CD4 <100 cells/mm3 compared
with 200-350 cells/mm3, an absolute difference of 237 years
lost per 1000 person years (24%). If we compare this with the
UK population estimates shown in table 3, the difference in
potential years lost is about 9%, 15%, and 33% for those who
start antiretroviral therapy with a CD4 count 200-350, 100-199,
and <100 cells/mm3, respectively⇓. As the life expectancy for
the general UK population (weighted by the sex proportion of
the HIV positive cohort) is about 58.8 years at the exact age of
20, the loss in life expectancy from the high to low CD4 groups
is 5.4, 17.8, and 20.9 years, respectively. Of note, 5895 out of
14 001 (42%) patients in UK CHIC had a CD4 count <200
cells/mm3 within three months of diagnosis.
In sensitivity analyses that varied the adjustment to rate of death
in the open age group (≥65), the life expectancy at the exact
age of 20 varied from 49.8 (no adjustment) to 37.9 for a rate
ratio of 6 (maximum adjustment considered). We estimated this
life expectancy to be 41.1 years (see table 2), using the observed
average rate ratio in the 55-59 and 60-64 groups, which was
2.56. For comparison, life expectancy was 42.7 and 40.3 years
with 2 and 3 as plausible limits of the rate ratio adjustment.
We found little evidence of a difference in life expectancy
between white and non-white groups once sex had been
accounted for, but estimates were imprecise because of
imbalances in the distribution of ethnicity by sex and the
heterogeneous nature of the non-white group. We also found
that restricting analyses to those who survived at least six months
after starting antiretroviral therapy improved life expectancy at
age 20 (overall for period 1996-2008) by less than two years.
We repeated analyses stratifying by period of starting
antiretroviral therapy instead of period of follow-up, omitting
2005-8 as there was insufficient follow-up for patients starting
treatment in the most recent years. As expected, we found a
similar strong trend of improvement in health indicators over
the first three calendar periods (see appendix 2 on bmj.com).
Discussion
The life expectancy of people with HIV treated with
antiretroviral therapy in UK hospital clinics has substantially
increased over the period 1996-2008, but remains much lower
than that of the UK population. Women have a higher life
expectancy than men, which is only partially accounted for by
sex differences in the life expectancy of the background
population. Most importantly, life expectancy is strongly related
to the CD4 count at which individuals start treatment. Patients
who were diagnosed late or deferred treatment until their CD4
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count fell to below 200 cells/mm3 were estimated to have a life
expectancy at age 20 at least 10 years less than those who
conformed to current treatment guidelines, which suggest that
patients should start antiretroviral therapy once their CD4 count
has fallen below 350 cells/mm3.17 19 Furthermore, the effect of
delayed diagnosis and treatment is worse than our results suggest
as some people die without ever starting antiretroviral therapy.
This highlights the need to identify people infected with HIV
early in the course of their infection, before substantial CD4
loss has occurred.
Strengths and limitations of study
In the UK in 2008 an estimated 45 893 people with HIV were
receiving antiretroviral therapy.20 We included 17 661
individuals in our analyses (about 38% of all treated patients)
and therefore results should be broadly applicable to a
population of people with HIV who start antiretroviral therapy
with a CD4 cell count below 350 cells/mm3 in the UK. Although
our findings might not be generalisable to settings other than
the UK, they will contribute to comparisons of life expectancy
across different settings. Our results do not apply to untreated
patients or those infected with HIV who have yet to receive a
diagnosis or access care. We excluded patients with a history
of use of injected drugs as they have higher mortality,7
particularly if they also have hepatitis B or C, and we were
unable to analyse drug users separately as numbers were too
small. There might have been some misclassification of users
of injected drugs as the dataset includes information only on
the most likely route of HIV infection rather than ongoing
injected drug use; however, we believe that anymisclassification
is likely to be small.
The estimates of life expectancy could be biased upwards
because of under-ascertainment of deaths, but regular attempts
are made to minimise this through the triangulation of
information on deaths held by the UKCHIC Study, surveillance
studies from the Health Protection Agency Centre for Infections,
and the death registry of the Office for National Statistics (ONS).
Furthermore, through anonymous linkage of data from patients
thought to be attending more than one clinic, regular attempts
are made to ensure that the denominator of patients under
follow-up is accurate and that loss to follow-up is minimised.21
This is particularly important in London, where patients might
access several different sites for their care.
Results should be interpreted with caution because we
partitioned data into subsets to construct life tables for
subgroups, unlike in multivariable regression where adjusted
estimates are the norm.We could not control for lifestyle factors
that could be associated both with late treatment and with a
poorer life expectancy, such as smoking or socioeconomic
position. The estimates of life expectancy are based on
extrapolations of the age and sex specific mortality rates
observed during the study period in the actual cohort, which are
then applied to a hypothetical cohort as if they applied to
individuals throughout their lives. The validity of this
assumption could be greatest for patients with persistently
suppressed viral loads.
Implications of findings
The improvement in life expectancy since 1996 is probably due
to several factors: a greater proportion of patients with high
CD4 counts, better antiretroviral therapy, changing
demographics of the population of patients (namely, more
women and immigrants from sub-Saharan Africa), and an
upward trend in the population life expectancy. The patients
treated in earlier years started therapy with more advanced HIV
disease, were more likely to develop drug resistant HIV because
of pre-treatment with one or two antiretroviral drugs,22 and
received regimens that were inferior to those currently prescribed
in terms of viral suppression, pill burden, toxicity, and serious
adverse effects.4 Improvements in treatment are unlikely to be
only pharmacological: increasing experience among physicians
could also have affected survival.23Non-adherence to treatment
can result in the development of drug resistance, which limits
the number of treatment options available to patients.
Interruptions to treatment are associated with increased risk of
virological rebound and serious non-AIDS events, as reported
by the Strategies for Management of Anti-Retroviral Therapy
(SMART) trial.24 Interrupting treatment probably became less
common after the results of the trial were reported, which could
have contributed to the increase in life expectancy after 2006.25
Modern first line regimens are more robust than earlier
regimens.26 There has been a decline in transmission of drug
resistant virus,27 and adherence has been improved by once daily
treatment and coformulation of medications, all of which
contribute to better virological control and, ultimately, greater
life expectancy.
The higher life expectancy in women in the general population
is magnified in those with HIV. This could be because of earlier
diagnosis through screening in antenatal clinics28 before women
have a low CD4 count, late presentation in men,29 or sex
differences in lifestyle factors that are exaggerated in patients
(for example, smoking, alcohol, and drug misuse are common
in men who have sex with men but not in women from
sub-Saharan Africa). Alternatively, there could be bias from
loss to follow-up and consequent under-ascertainment of death
in women. It is important to further understand this discrepancy
and formulate policy to ensure that there are equal opportunities
to achieve the same outcome in men and women.
The data on life expectancy stratified by CD4 count show that
an important driver of the lower life expectancy in people with
HIV comparedwith the general population is that patients started
treatment at a lower CD4 count than recommended by
guidelines.17 At the start of treatment, mortality is highest for
those with lowest CD4 count,7 and even in those who survive
the first three years of treatment, CD4 count at start of
antiretroviral therapy remains prognostic.30 A review of deaths
among treated patients with HIV in the Royal Free Hospital in
London from 1998 to 2003 cited late presentation, delayed
uptake of antiretroviral therapy, and previous use of treatment
combinations now viewed as suboptimal as contributory
factors.31 A high proportion of patients in UK CHIC started
treatment with CD4 count <200 cells/mm3.32 This proportion is
consistent with that seen in many other European settings, where
many people do not receive a diagnosis of HIV infection until
their CD4 counts have already fallen to low levels. Late
presentation, however, is only a partial explanation: patients,
particularly if they have no symptoms, might have delayed
starting treatment because of a reluctance to embark on a lifelong
commitment to take antiretroviral drugs, many of which have
a poor toxicity/tolerability profile. Before starting treatment,
many patients had substantial gaps between CD4 assessments,
reflecting irregular clinic attendance.32
In addition to deaths from AIDS defining diagnoses, people
with HIV experience higher rates of non-AIDS deaths than the
general population, which could be due to HIV infection,
adverse events associated with treatment for HIV, or lifestyle
factors. The prevalence of smoking, drugmisuse, and alcoholism
are all higher among people with HIV, which leads to increased
deaths from cardiovascular disease, cancer, liver disease, suicide,
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overdose, and injury. We were unable to account for lifestyle
factors or cause of death in this analysis.
Comparison with other studies
The life expectancy in our study is somewhat lower than that
estimated in a study by the Antiretroviral Therapy Cohort
Collaboration, although the increase in life expectancy of 13
years between 1996 and 2005 is similar.16 The lower life
expectancy in UK CHIC could be because of the inclusion of
patients previously treated with one or two antiretroviral drugs
or more complete ascertainment of death. Estimates of life
expectancy and trends over time based on a study in Denmark
are similar to our estimates.12 Compared with the general
population, standardised mortality rates for people with HIV
treated for at least six months have been estimated to vary from
1.05 (95% confidence interval 0.82 to 1.35) to 73.7 (46.4 to
116.9), depending on transmission risk group and clinical stage
at baseline and CD4 count and viral load at six months.3 Recent
studies have estimated life expectancy or standardised mortality
rates for highly selected groups of people with HIV that
approach those of the comparator uninfected population. For
example, in the Netherlands the number of years of life lost by
asymptomatic patients with a recent diagnosis varied from 0.4
years in those aged 25 at diagnosis to 1.4 years in those aged
55.33 In this group of patients, the median CD4 cell count was
480 cells/mm3 (interquartile range 360-650). The Collaboration
of Observational HIV Epidemiological Research in Europe
(COHERE) found that death rates among men, but not women,
with CD4 counts >500 cells/mm3 reached those of the matched
general population after at least three years’ receipt of
antiretroviral therapy with counts above that threshold.34 These
studies show what can be achieved if patients receive an early
diagnosis, avoid compromising their immune system and the
attendant morbidities35 and are successfully treated to restore
their CD4 count to a level approaching normality.
Conclusions
Life expectancy among people with HIV has considerably
improved in the UK between 1996 and 2008, and we should
expect further improvements for patients starting antiretroviral
therapy now with improved modern drugs and new guidelines
recommending earlier treatment. Our study shows the longevity
of patients who started antiretroviral therapy with a CD4 count
of 200-350 cells/mm3. These data can be incorporated into
models for life insurance, pensions, and healthcare planning,
but most of all communicated to patients to help them manage
their lives better. Furthermore, the clear impact of low CD4
count on life expectancy implies that it is particularly important
to diagnose HIV infection at an early stage. This would benefit
both patients and healthcare systems as the patient would
experience increased life expectancy and the healthcare system
a reduction in the costs associated with lower CD4 count at
diagnosis, including hospital treatment or admission, or both.
Our findings strongly support the concept of more widespread
testing for HIV, especially initiatives to achieve universal
testing. It is also of clear benefit to the patient to have the
prognosis made in terms of their life expectancy, and this might
have considerable impact on patients’ uptake of testing.
This work was presented in part at the Tenth International Congress on
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Tables
Table 1| Characteristics of patients at start of combination antiretroviral therapy (by period of initiation of treatment (n=17 661) (P<0.001
for all variables). Figures are numbers (percentage) of patients unless stated otherwise
1996-2008 (n=17 661)2006-8 (n=4023)2003-5 (n=4180)2000-2 (n=3609)1996-9 (n=5849)Variable
Age (years):
37 (32-43)38 (32-44)37 (32-43)36 (32-42)36 (31-42)Median (IQR)
3048 (17)661 (16)694 (17)644 (18)1049 (18)16-29
8578 (49)1744 (43)1989 (48)1826 (51)3019 (52)30-39
4372 (25)1202 (30)1088 (26)820 (23)1262 (22)40-49
1298 (7.4)314 (7.8)311 (7.4)243 (6.7)430 (7.4)50-59
365 (2.1)102 (2.5)98 (2.3)76 (2.1)89 (1.5)≥60
13 302 (75)2996 (75)2949 (71)2548 (70)4809 (82)Men
10 198 (58)2193 (55)2097 (50)1823 (50)4085 (70)White
Risk factor for transmission:
9624 (54)2025 (50)2067 (49)1697 (47)3835 (66)Men who have sex with
men
6494 (37)1521 (38)1863 (45)1593 (44)1517 (26)Heterosexual
1543 (8.7)477 (11.9)250 (6.0)319 (8.8)497 (8.5)Other or unknown
CD4 cell count (cells/mm3)*:
166 (75-241)200 (113-263)174 (90-235)149 (61-225)140 (50-230)Median (IQR)
4585 (31)805 (22)955 (27)1026 (35)1799 (39)<100
4434 (30)994 (27)1183 (33)943 (32)1314 (28)100-199
5849 (39)1894 (51)1436 (40)982 (33)1537 (33)200-350
4590 (26)576 (14)828 (20)1007 (28)2179 (37)AIDS stage C† diagnosis
HIV-1 RNA level (log10 copies/mL)‡:
4.9 (4.1-5.4)4.7 (4.0-5.2)4.9 (4.2-5.4)5.0 (4.3-5.5)4.9 (4.1-5.4)Median (IQR)
3065 (22)958 (26)739 (21)495 (17)873 (22)<4.00
5005 (35)1436 (38)1208 (34)997 (35)1364 (35)4.00-4.99
6062 (43)1341 (36)1627 (46)1397 (48)1697 (43)≥5.00
14293 (81)3853 (96)4014 (96)3281 (91)3145 (54)Naive at start of triple ART§
Initial drug regimen:
5662 (32)1207 (30)819 (20)494 (14)3142 (54)PI based
9769 (55)2586 (64)3019 (72)2387 (66)1777 (30)NNRTI based
633 (3.6)25 (0.6)82 (2.0)234 (6.5)292 (5.0)Triple NRTI
1134 (6.4)128 (3.2)190 (4.6)457 (13)359 (6.1)Four or more drugs
463 (2.6)77 (1.9)70 (1.7)37 (1.0)279 (4.8)Other or unknown
IQR=interquartile range; ART=antiretroviral therapy; PI=protease inhibitor; NNRTI=non-nucleoside reverse transcriptase inhibitor; NRTI=nucleoside reverse
transcriptase inhibitor.
*Available for 14 868 (84%) patients.
†Center for Disease Control (CDC) clinical stage.
‡Available for 14 132 (80%) patients.
§Previous exposure to one or two antiretroviral drugs before start of combination therapy.
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Table 2| Health indicators for overall treated population of patients (age ≥20) who started antiretroviral therapy in 1996-2008 by period of
follow-up
1996-20082006-82003-52000-21996-9Measure
17 66115 15212 02984935471No of patients in follow-up
1248328341308271No of deaths
Mortality rates per 1000 person years (95% CI):
13.7 (12.9 to 14.5)9.5 (8.6 to 10.6)12.2 (11.0 to 13.6)16.3 (14.6 to 18.3)26.8 (23.7 to 30.1)Overall
11.7 (10.9 to 12.6)7.5 (6.4 to 8.8)10.0 (8.6 to 11.5)14.5 (12.7 to 16.7)22.7 (19.5 to 26.2)Age 20-44
285.3175.1248.5365.5611.3Potential years of life lost for ages 20-64 (per 1000 person years)
Life expectancy (years):
41.1 (0.5)45.8 (1.7)43.1 (1.0)39.4 (1.2)30.0 (1.2)At exact age 20 (SE*)
30.8 (0.2)35.6 (0.5)31.6 (0.5)28.2 (0.6)20.0 (0.6)At exact age 35 (SE*)
77.382.381.674.760.8% surviving from 20 to 44
* Standard error for estimated life expectancy.
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Table 3| Health indicators stratified by sex for treated population who started antiretroviral therapy 1996-2008 (n=17 661) and for the UK
population (1996-2006)
UK population (1996-2006)People with HIV (1996-2008)
Measure WomenMenWomenMen
——435913 302No of patients
——1901058No of deaths
Mortality rates per 1000 person years (95% CI):
13.713.49.4 (8.1 to 10.8)13.7 (12.9 to 14.5)Overall
0.61.28.9 (7.6 to 10.5)11.7 (10.9 to 12.6)Age 20-44
18.935.4229.3291.4Potential years of life lost for ages 20-64 (per 1000 person years)
Life expectancy (years):
61.657.850.2 (0.45)39.5 (0.45)At exact age 20 (SE*)
46.943.537.7 (0.24)30.1 (0.24)At exact age 35 (SE*)
98.497.084.374.6% surviving from 20 to 44
*Standard error for estimated life expectancy.
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Table 4| Health indicators for patients who had not previously received antiretroviral drugs and started combination antiretroviral therapy
in 2000-8 stratified by CD4 cell count at start of treatment (n=9657)
CD4 cell count
Measure 200-350 cells/mm3100-199 cells/mm3<100 cells/mm3
402829402689No of patients
75101173No of deaths
Mortality rates per 1000 person years (95% CI):
5.9 (4.7 to 7.4)9.2 (7.6 to 11.3)16.7 (14.4 to 19.4)Overall
5.1 (3.8 to 6.8)6.8 (5.2 to 8.9)14.5 (12.0 to 17.6)Age 20-44
120.5184.9357.7Potential years of life lost for ages 20-64 (per 1000 person years)
Life expectancy (years):
53.4 (1.2)41.0 (2.2)37.9 (1.3)At exact age 20 (SE*)
40.5 (1.1)30.4 (0.7)27.0 (0.7)At exact age 35 (SE*)
89.282.775.0% surviving from 20 to 44
*Standard error for estimated life expectancy.
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Figures
Fig 1 Distribution of current CD4 count by period of follow-up
Fig 2 Life expectancy from age 20-65 of people who started antiretroviral therapy in 2000-8 by CD4 cell count group at
start of antiretroviral therapy compared with that of UK population (2000-6 women and men)
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